Sugi Predict

Sugi Predict / Compounds / SCHEMBL22208142

SCHEMBL22208142

SCHEMBL22208142

CCOC(=O)c1cnc(Cl)c(F)c1NC(=O)NC(=O)C(Cl)(Cl)Cl

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.39
▸ MAPT P10636 5/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ HPGD P15428 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ PMP22 Q01453 1/20 0.39
▸ PDE4B Q07343 5/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ GAA P10253 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ PDE5A O76074 1/20 0.37
▸ TP53 P04637 3/20 0.36
▸ THRB P10828 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29418903 1.00 KDM4E (0.39) KDM4EMAPTMEN1KMT2AHPGD
SCHEMBL31442170 0.90 ATR (0.37) KDM4EMAPTALDH1A1GAA
SCHEMBL22208117 0.88 MAPT (0.39) KDM4EMAPTMEN1KMT2AHPGD
SCHEMBL22208145 0.88 KMT2A (0.40) KDM4EMAPTMEN1KMT2AHPGD
SCHEMBL31551785 0.86 KDM4E (0.39) KDM4EMAPTMEN1KMT2AHPGD
SCHEMBL22208155 0.85 KDM4E (0.39) KDM4EMAPTMEN1KMT2APDE4B
SCHEMBL30064873 0.85 KDM4E (0.39) KDM4EMAPTMEN1KMT2APDE4B
SCHEMBL22208066 0.84 KDM4E (0.40) KDM4EMAPTMEN1KMT2APDE4B
SCHEMBL25783624 0.83 MAPT (0.38) KDM4EMAPTMEN1KMT2AHPGD
SCHEMBL31323485 0.83 MAPT (0.42) KDM4EMAPTMEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
US-20260109716-A1 CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO ARVINAS OPERATIONS, INC. (US) 2026-04-23 — — US disclosed
EP-4655073-A2 CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO Arvinas Operations, Inc. (US) 2025-12-03 — — EP disclosed
US-12448399-B2 Cereblon-based KRAS degrading PROTACs and uses related thereto ARVINAS OPERATIONS, INC. (US) 2025-10-21 — — US disclosed
US-20250270206-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS NNSA 2025-08-28 — — US disclosed
US-20250206732-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS ARVINAS OPERATIONS, INC. 2025-06-26 — — US disclosed
US-20250084079-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS LEIDOS BIOMEDICAL RESEARCH, INC. 2025-03-13 — — US disclosed
WO-2025053850-A1 COVALENT KRAS-BINDING COMPOUNDS FOR MEDICAL TREATMENT HYKU BIOSCIENCES INC. (US) 2025-03-13 — — WO disclosed
US-20240409558-A1 IRREVERSIBLE INHIBITORS OF KRAS BIOMEA FUSION, INC. 2024-12-12 — — US disclosed
US-20240309020-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2024-09-19 — — US disclosed
WO-2022194191-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12D GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) 2022-09-22 — — WO disclosed
EP-4021444-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-07-06 — — EP disclosed
WO-2022031678-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-02-10 — — WO disclosed
WO-2022015375-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-01-20 — — WO disclosed
EP-3908283-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2021-11-17 — — EP disclosed
WO-2021041671-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-04 — — WO disclosed
WO-2021041671-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-04 — — WO disclosed
US-20200331911-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2020-10-22 — — US disclosed
US-20200331911-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2020-10-22 — — US disclosed
WO-2020146613-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448399-B2 Cereblon-based KRAS degrading PROTACs and uses related thereto CRBN, KRAS, WEE1 KDM4E 1273/4885MAPT 3819/4885MEN1 409/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS KDM4E 2825/4885MAPT 4652/4885MEN1 924/4885
US-20240409558-A1 IRREVERSIBLE INHIBITORS OF KRAS KRAS, NRAS, TP53 KDM4E 3532/4885MAPT 4716/4885MEN1 1189/4885
US-20250084079-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS KRAS, NRAS, HRAS KDM4E 3456/4885MAPT 213/4885MEN1 149/4885
US-20200331911-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS KDM4E 3689/4885MAPT 3928/4885MEN1 348/4885
US-20250270206-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS KRAS, NRAS, HRAS KDM4E 3717/4885MAPT 358/4885MEN1 161/4885
US-20250206732-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS KRAS, MDM2, VHL KDM4E 2092/4885MAPT 3740/4885MEN1 2222/4885
US-20260109716-A1 CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO KRAS, CRBN, HRAS KDM4E 1792/4885MAPT 4843/4885MEN1 1093/4885
US-20240309020-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS KDM4E 3340/4885MAPT 3682/4885MEN1 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.